SCHEMBL13242569

SCHEMBL13242569

COc1cc(C(=O)OCCCC(CO[N+](=O)[O-])O[N+](=O)[O-])ccc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.59
KDM4E B2RXH2 2/20 0.53
POLB P06746 1/20 0.53
HSD17B2 P37059 1/20 0.49
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA9 Q16790 1/20 0.42
SLC22A6 Q4U2R8 1/20 0.40
SLC22A8 Q8TCC7 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
HTT P42858 2/20 0.40
PTGS1 P23219 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1975777 0.97 HDAC6 (0.61) HDAC6KDM4EPOLBHSD17B2KMT2A
SCHEMBL13242566 0.94 KDM4E (0.55) HDAC6KDM4EPOLBHSD17B2KMT2A
SCHEMBL13242567 0.88 HSD17B2 (0.54) HDAC6KDM4EPOLBHSD17B2KMT2A
SCHEMBL12554684 0.84 CA12 (0.45) HDAC6KDM4EPOLBCA12CA1
SCHEMBL13242559 0.84 HDAC6 (0.71) HDAC6KDM4EPOLBHSD17B2KMT2A
SCHEMBL1830326 0.84 HDAC6 (0.76) HDAC6KDM4EPOLBHSD17B2KMT2A
SCHEMBL13242556 0.82 HDAC6 (0.78) HDAC6KDM4EPOLBHSD17B2KMT2A
SCHEMBL13242563 0.82 HDAC6 (0.78) HDAC6KDM4EPOLBHSD17B2KMT2A
SCHEMBL13242538 0.82 MET (0.57) CA12CA1CA2CA4CA9
SCHEMBL13242561 0.81 KDM4E (0.67) HDAC6KDM4EPOLBHSD17B2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179192-A1 USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN NICOX S.A. (FR) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179192-A1 USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN NOS1, NOS2, NOS3 HDAC6 1596/4885KDM4E 3010/4885POLB 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.